Avalo Therapeutics (AVTX) Accumulated Depreciation & Amortization (2016 - 2024)
Historic Accumulated Depreciation & Amortization for Avalo Therapeutics (AVTX) over the last 11 years, with Q4 2024 value amounting to $710000.0.
- Avalo Therapeutics' Accumulated Depreciation & Amortization rose 3099.63% to $710000.0 in Q4 2024 from the same period last year, while for Dec 2024 it was $710000.0, marking a year-over-year increase of 3099.63%. This contributed to the annual value of $710000.0 for FY2024, which is 3099.63% up from last year.
- Latest data reveals that Avalo Therapeutics reported Accumulated Depreciation & Amortization of $710000.0 as of Q4 2024, which was up 3099.63% from $542000.0 recorded in Q4 2023.
- In the past 5 years, Avalo Therapeutics' Accumulated Depreciation & Amortization ranged from a high of $710000.0 in Q4 2024 and a low of $177000.0 during Q4 2020
- Its 5-year average for Accumulated Depreciation & Amortization is $425800.0, with a median of $414000.0 in 2022.
- Per our database at Business Quant, Avalo Therapeutics' Accumulated Depreciation & Amortization plummeted by 9544.23% in 2020 and then soared by 6158.19% in 2021.
- Quarter analysis of 5 years shows Avalo Therapeutics' Accumulated Depreciation & Amortization stood at $177000.0 in 2020, then surged by 61.58% to $286000.0 in 2021, then skyrocketed by 44.76% to $414000.0 in 2022, then skyrocketed by 30.92% to $542000.0 in 2023, then soared by 31.0% to $710000.0 in 2024.
- Its last three reported values are $710000.0 in Q4 2024, $542000.0 for Q4 2023, and $414000.0 during Q4 2022.